About Us | NovaTechs

Our Story

From nano-pharmaceuticals to revolutionary embolic solutions

Foundation & Early Years

NovaTechs BV was founded in 2020 in the Netherlands with a mission to revolutionize the landscape of drug delivery in oncology. Our journey began with a focus on nano-pharmaceuticals and targeted therapeutics. We immersed ourselves in research, developing innovative delivery platforms that included liposomes, nano-emulsions, and polymeric hydrogels.

As we navigated the complexities of drug delivery, we recognized a critical gap in the treatment of cancer, specifically, the need for more effective and safer solutions in interventional oncology. This realization sparked a transformative pivot in our mission, leading us to focus exclusively on this vital area of patient care.

The Birth of NovaSeal®

In 2023, after years of rigorous research and development, we proudly introduced NovaSeal®, our flagship liquid embolic agent designed to revolutionize cancer treatment. NovaSeal stands at the intersection of innovation and compassion, engineered to provide targeted therapy that minimizes collateral damage to healthy tissues while maximizing therapeutic impact on tumors.

What sets NovaSeal apart is its unique formulation, which leverages bio-based materials to ensure both efficacy and safety. Our commitment to sustainability is woven into every aspect of our product, reflecting our dedication not just to patients but also to the planet.

Bio-based Materials

Enhanced Safety

Targeted Therapy

Current Status & Achievements

Since its strategic pivot, NovaTechs has achieved significant milestones, including the completion of in vitro studies and non-GLP in vivo validation studies, as well as the development of a stable, bio-based formulation. Our team has forged valuable partnerships with academic institutions, clinical organizations, and industry leaders, while also obtaining public funding to progress toward GLP studies and regulatory submissions.

Currently, NovaTechs is based at the Brightlands Chemelot Campus, a premier innovation hub focused on health and materials. We are laying the groundwork for first-in-human trials and preparing for global market entry.

In Vitro Studies

Completed

In Vivo Validation

Non-GLP Completed

Partnerships

Academic & Clinical

Funding

Public Support

Mission & Vision

Inspired by wisdom, driven by innovation

Our Mission

NovaTechs is dedicated to transforming the lives of cancer patients by enhancing health outcomes and quality of life through advanced, non-toxic, and less invasive pharmaceutical solutions. Our products meet the highest standards of quality and efficacy by bridging the gap between innovative ideas, scientific research, and practical applications.

Our Vision

Inspired by the wisdom of the great Iranian philosopher and physician, Avicenna, that "starving cancer cells is better than stabbing them," our vision is to block the blood supply to cancer cells using gel-based formulations. We strive to create a healthier future for communities worldwide by prioritizing patient needs and fostering a culture of innovation and collaboration.

Our Commitment

Founded on profound expertise and a deep sense of purpose, our unwavering commitment is to advance clinically relevant, sustainable, and user-friendly embolic solutions, making a significant impact in the battle with cancer.

Our Values

The principles that guide our innovation and growth

Innovation

Continuously pushing boundaries in medical technology to create breakthrough solutions.

Sustainability

Committed to environmental responsibility through bio-based materials and eco-friendly processes.

Collaboration

Building strong partnerships with academic institutions, healthcare providers, and industry leaders.

Safety

Prioritizing patient safety through rigorous testing and non-toxic formulations.

Excellence

Maintaining the highest standards in research, development, and product quality.

Compassion

Putting patients first and understanding the human impact of our innovations.

Our Team

Meet the experts behind NovaTechs innovation

Dr. Sarah Johnson

Founder & CEO

Leading NovaTechs with over 15 years of experience in pharmaceutical development and a passion for innovative cancer treatments.

Dr. Michael Chen

Chief Technology Officer

Expert in gel-based drug delivery systems with a focus on interventional radiology and minimally invasive procedures.

Dr. Emily Rodriguez

Lead Scientist

Specialized in bio-based materials and sustainable pharmaceutical formulations with expertise in clinical trial design.

Search NovaTechs

About NovaTechs